Please login to the form below

Not currently logged in
Email:
Password:

gouty arthritis

This page shows the latest gouty arthritis news and features for those working in and with pharma, biotech and healthcare.

CV data sets up Novartis' Ilaris for blockbuster sales

CV data sets up Novartis' Ilaris for blockbuster sales

Ilaris is an interleukin-1 beta inhibitor and has been on sale since 2009, gradually picking up approvals for a range of inflammatory diseases including juvenile-onset rheumatoid arthritis, gouty arthritis

Latest news

  • Novartis' Ilaris wins three new FDA approvals Novartis' Ilaris wins three new FDA approvals

    The three new indications add to Ilaris' existing approvals in Adult-Onset Still's Disease (AOSD), gouty arthritis, and autoinflammatory condition Systemic Juvenile Idiopathic Arthritis ( SJIA), the most aggressive form of ... juvenile arthritis.

  • Grunenthal to market MSD’s pain drug Grunenthal to market MSD’s pain drug

    The drug has been available in Europe via MSD since the early 2000s and is indicated to relieve pain in people with osteoarthritis, rheumatoid arthritis and acute gouty arthritis.

  • Novartis wins childhood arthritis indication for Ilaris in EU Novartis wins childhood arthritis indication for Ilaris in EU

    Novartis wins childhood arthritis indication for Ilaris in EU. EC gives green light to drug for the treatment of systemic juvenile idiopathic arthritis. ... gouty arthritis, which is a painful inflammation of the joints.

  • Novartis gets FDA green light for new Ilaris indication Novartis gets FDA green light for new Ilaris indication

    Novartis gets FDA green light for new Ilaris indication. Immunotherapeutic wins US approval for severe form of childhood arthritis. ... arthritis. Efforts to get a gouty arthritis indication in the US were knocked back in 2011, however, when the FDA -

  • Novartis' Ilaris cleared for gouty arthritis in EU Novartis' Ilaris cleared for gouty arthritis in EU

    Novartis' Ilaris cleared for gouty arthritis in EU. First biologic drug approved for condition in Europe. ... Novartis' Ilaris has become the first biologic drug to be approved in the EU to treat the symptoms of gouty arthritis in another gain for the

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics